ProShare Advisors
IMNM icon

ProShare Advisors’s Immunome IMNM Stock Holding History

ProShare Advisors’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$293K Sell
13,804
-995
-7% -$21.3K ﹤0.01% 1433
2026
Q1 		$324K Sell
14,799
-2,325
-14% -$51.7K ﹤0.01% 1294
2025
Q4 		$368K Buy
17,124
+3,930
+30% +$69K ﹤0.01% 1324
2025
Q3 		$155K Sell
13,194
-1,913
-13% -$19K ﹤0.01% 1758
2025
Q2 		$140K Sell
15,107
-241
-2% -$1.98K ﹤0.01% 1803
2025
Q1 		$103K Buy
15,348
+871
+6% +$8.36K ﹤0.01% 1828
2024
Q4 		$154K Buy
+14,477
New +$175K ﹤0.01% 1964

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

ProShare Advisors's IMNM Position: Q2 2026 in Review

ProShare Advisors reduced its Immunome (IMNM) stake by 6.7% in Q2 2026, selling an estimated $21.3K and leaving 13,804 shares worth $293K. The position accounts for ﹤0.01% of the portfolio, ranked #1433.

ProShare Advisors first reported a position in IMNM in Q4 2024 and has held it in 7 quarters since. The position peaked at $368K in Q4 2025. 203 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • ProShare Advisors held 13,804 shares of Immunome worth $293K as of Q2 2026.
  • ProShare Advisors sold 995 Immunome shares in Q2 2026, an estimated $21.3K.
  • Immunome made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1433 holding.
  • ProShare Advisors first reported a position in Immunome in Q4 2024 and has held it in 7 quarters since.
  • ProShare Advisors's Immunome position peaked at $368K in Q4 2025.
  • 203 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.